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Introduction: The purpose of this study was to evaluate the predictive 
role of quantitative metabolic parameters using total lesion glycoly-
sis (TLG) in 18F-2-fluoro-2-deoxyglucose-positron emission tomog-
raphy/computed tomography for developing gefitinib resistance in 
epidermal growth factor receptor (EGFR)-mutant non–small-cell 
lung cancer (NSCLC) patients treated with first-line gefitinib.
Methods: A total of 75 NSCLC patients harboring activating EGFR 
mutation and receiving first-line gefitinib were analyzed. Whole-
body 18F-2-fluoro-2-deoxyglucose positron emission tomography/
computed tomography scans were acquired before first-line gefitinib. 
The maximal standardized uptake value and TLG of all lesions were 
calculated. Maximal standardized uptake value and TLG were cat-
egorized using the tertile cutoff. Treatment outcomes were compared 
between groups.
Results: Overall response rate of gefitinib was 69.4%, and median 
progression-free survival (PFS) of gefitinib was 11.5 months. Overall 
response rates were similar between low, intermediate, and high TLG 
groups (68.0% versus 76.0% versus 68.0%, p = 0.274). However, 
PFS significantly differed by TLG groups, and high TLG was asso-
ciated with shorter PFS (7.2 months in high TLG; 11.9 months in 
intermediate TLG; and 24.2 months in low, p < 0.001). Multivariate 
models adjusted for disease status and response to gefitinib showed 
that TLG was an independent predictive factor for PFS. TLG was 
also significantly associated with overall survival (p = 0.005).
Conclusion: TLG can predict PFS and development of gefitinib 
resistance in EGFR-mutant NSCLC patients treated with first-line 
gefitinib. Baseline metabolic tumor burdens measured with TLG 
before first-line gefitinib will be of great help in predicting time to 
acquired resistance.
Key Words: gefitinib, resistance, EGFR mutation, PET/CT, total 
lesion glycolysis.
(J Thorac Oncol. 2015;10: 1189–1194)
Epidermal growth factor receptor (EGFR) mutation is a well-known predictive and prognostic factor for EGFR tyrosine 
kinase inhibitors (TKIs) efficacy in non–small-cell lung can-
cer (NSCLC),1–3 and first-line EGFR TKIs have become stan-
dard treatment for stage IIIB/IV NSCLC harboring activating 
EGFR mutations.4,5 However, acquired TKI resistance is inev-
itable in almost all patients, and progression-free survival 
(PFS) of EGFR TKI has reached 9 to 11 months.4–6 Potential 
mechanisms of resistance to gefitinib include EGFR T790M 
mutation in exon 20, c-Met amplification, and other bypass 
signaling activation.7 Although tumor burden and preexisting 
EGFR T790M mutation at baseline decrease PFS in NSCLC 
patients with activating EGFR mutation who received EGFR 
TKIs, it is difficult for clinicians to predict when resistance 
will occur during EGFR TKI treatment.8,9
18F-2-Fluoro-2-deoxyglucose (FDG)-positron emis-
sion tomography/computed tomography (PET/CT) is widely 
used for pretreatment staging, restaging, response monitoring, 
evaluation of tumor aggressiveness, and prognostication. In 
patients with NSCLC, FDG-PET/CT has an established role 
in monitoring treatment response10,11 and prognosis.12 With 
FDG-PET/CT, the maximal standard uptake value (SUVmax) 
has been used as an index for metabolic activity. Recently, 
there is a growing recognition of volume-based metabolic 
parameters, such as total lesion glycolysis (TLG), as prom-
ising quantitative PET indices.13,14 Compared with SUVmax, 
TLG has an advantage of reflecting both the metabolic activity 
and the tumor burden. However, the potential role for TLG in 
predicting EGFR TKI resistance has not yet been elucidated. 
The purpose of this study was to evaluate the predictive role 
of quantitative metabolic parameters using TLG in FDG-PET/
CT for the development of gefitinib resistance in EGFR-
mutant NSCLC patients treated with first-line gefitinib.
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PATIENTS AND METHOD
Study Patients and Gefitinib Treatment
We retrospectively analyzed a consecutive database15–17 
of NSCLC patients who were treated with gefitinib at Seoul 
National University Hospital between May 2007 and January 
2012. A total of 75 patients who met the following inclusion 
criteria were analyzed: pathologically confirmed stage IIIB/IV 
or recurred, chemotherapy-naive NSCLC; activating EGFR 
mutation including microdeletion in exon 19 or missense 
mutation in exon 21 (L858R); receiving first-line gefitinib as 
palliative chemotherapy; and FDG-PET/CT conducted before 
first-line gefitinib.
Clinicopathologic parameters were retrieved from 
electronic medical records, including age, sex, disease sta-
tus, smoking history (never-smoker; smoked ≤100 cigarettes 
in lifetime; and current or ex-smoker), Eastern Cooperative 
Oncology Group performance status, and EGFR mutation sta-
tus. Patients received gefitinib at a dose of 250 mg per day 
until disease progression or unacceptable toxicities. During 
gefitinib treatment, CT scans were routinely performed every 
8 to 12 weeks for evaluation of response and progression. In 
case of clinical suspicion for disease progression, CT scans 
were performed earlier. Treatment response was evaluated 
based on the Response Evaluation Criteria in Solid Tumors 
criteria (RECIST) version 1.1.18 Development of gefitinib 
resistance was defined by systemic progression of disease by 
RECIST version 1.1 during treatment with gefitinib. Mutation 
analyses of EGFR exon 18, 19, 20, and 21 including EGFR 
T790M mutation were performed by direct DNA sequencing 
as previously described.17,19
FDG-PET/CT and Image Analysis
Whole-body FDG-PET/CT scans were acquired before 
first-line gefitinib treatment. In all patients, FDG-PET/CT 
images were acquired according to our standard imaging 
protocol, using dedicated PET/CT scanners (Biograph 40 or 
Biograph 64, Siemens Healthcare, Germany). Patients fasted 
for at least 8 hours before FDG was injected intravenously. 
Patients were administered FDG (5.18 MBq/kg), and images 
were acquired 60 minutes after administration. CT scans were 
performed first for attenuation correction and lesion localiza-
tion, and emission scans were obtained from the skull base to 
the proximal thigh for 1 minute per bed. PET data reconstruc-
tion was done by an iterative algorithm. PET/CT images were 
reviewed by two experienced nuclear medicine physicians.
On a per-lesion basis, SUVmax and TLG values with 
three variable margin thresholds were acquired for analysis. 
TLG of a lesion was calculated as mean SUV (SUVmean) 
× metabolic tumor volume (MTV), which reflects both the 
metabolic activity and tumor burden. Details of the TLG-
measuring method were described in our previous study.20 
MTV for each threshold margin was measured by setting the 
margin thresholds as 50% of SUVmax for each lesion. In the 
image analysis, a spheroidal volume of interest (VOI) was 
drawn to include the entire lesion, and an isocontour VOI was 
automatically drawn by a dedicated software package (Syngo.
via, Siemens Healthcare). Afterward, the values of SUVmax, 
MTV, and SUVmean for the VOI were measured. If lesions 
were bulky and conglomerated so that discrimination of one 
lesion from another could not be achieved, the lesions were 
analyzed as a cluster. Measurement of these values was auto-
matically performed using the dedicated software and thus 
had a reproducibility of 100%. Finally, on the patient level, 
the SUVmax of a patient was defined as the highest SUVmax 
among all lesions, and TLG of a patient was defined as the 
sum of all lesions.
Statistical Analysis
Statistical analyses of categorical variables were per-
formed using Pearson’s χ2 test. PFS of gefitinib was deter-
mined as the interval between gefitinib administration, and 
the date when disease progression by RECIST version 1.1 
or death was first documented. Overall survival (OS) was 
measured from the initiation date of gefitinib to the date of 
death or the last follow-up visit. Median PFS and OS were 
calculated using the Kaplan–Meier method. Comparisons of 
survival between the different groups were made using the 
log-rank test. Multivariate analysis was performed using a 
Cox proportional hazard regression model. Discrimination 
for survival data was evaluated using the C statistic with con-
cordance index (C-index), which is similar in concept to the 
area under receiver-operating characteristic curve in the logis-
tic model, but appropriate for censored data.21 The C-index 
provides the probability that given two randomly selected 
patients, the patient with the worse outcome will in fact have 
a worse outcome. A two-sided p less than 0.05 was considered 
statistically significant. Analyses were completed with STATA 
software, version 12 (StataCorp LP, College Station, TX). 
This study was approved by the Institutional Review Board 
at Seoul National University Hospital (H-1204-021-403).The 
study was also conducted in accordance with the Principles of 
the Declaration of Helsinki.
RESULTS
Clinical Features
A total of 75 NSCLC patients with activating EGFR 
mutation were analyzed in this study. All patients were stage 
IIIB or IV and received first-line gefitinib as palliative che-
motherapy. The median follow-up duration was 35 months 
(range, 7–65 months). Median time between baseline PET/CT 
and initiation of gefitinib was 19 days (range 0–46 days). The 
clinicopathologic characteristics of the 75 patients are sum-
marized in Table 1. Nearly 60% of patients harbored a deletion 
mutation in EGFR exon 19, and none had concomitant KRAS 
or EGFR T790M mutation. The median patient age was 68 
years (range, 39–88 years). We used the tertile cutoff as a 
threshold for the TLG: low/intermediate, 102.8 and intermedi-
ate/high, 455.1. We used the tertile cutoff as a threshold for the 
SUVmax: low/intermediate, 10.6 and intermediate/high, 13.4.
Response to Gefitinib and 
Metabolic Parameters
The overall response rate (ORR) was 69.4% (complete 
remission, 2.7% [N = 2]; partial response, 66.7% [N = 50]). 
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Thirteen patients (17.3%) had stable disease; 5 patients 
(6.7%) had progressive disease; and 5 patients (6.7%) were 
not evaluable. ORRs were similar between the SUVmax 
groups (p = 0.793) and TLG groups (p = 0.274; Table 2). 
Clinicopathologic factors were not significantly differed by 
TLG groups (Table 2). Gefitinib outcomes were not differed 
between adenocarcinoma and other subtypes (ORR, 72.9% 
versus 81.8%, p = 0.534; median PFS, 11.9 versus 8.5 months, 
p = 0.297).
Survival Outcomes and Metabolic Parameters
Median PFS was 11.5 months (95% confidence inter-
val [CI]: 9.2–13.8 months), and median OS was 26.7 months 
(95% CI: 23.2–30.2 months). The correlation between TLG 
and survival was consistently associated with different cutoff 
levels of TLG in a dose-dependent manner (data not shown). 
Clinical characteristics and treatment outcomes by TLG are 
shown in Table 2. Clinical characteristics were comparable 
between the three TLG groups. PFS differed by TLG, and high 
TLG was associated with a shorter PFS (7.2 months in high 
TLG, 11.9 months in intermediate TLG, and 24.2 months in 
low; p < 0.001; Fig. 1A). Furthermore, TLG was significantly 
associated with OS proportionally (Fig. 1B). Univariate analy-
sis found that TLG, disease status, and response to gefitinib 
were significantly associated with PFS. Multivariate models 
adjusted for disease status and response to gefitinib showed 
that TLG was an independent predictive factor for PFS 
(Table 3). SUVmax was also associated with PFS but not OS 
(Fig. 2A and B). The C-index of SUVmax for PFS was lower 
than that of TLG (0.629 for SUVmax and 0.661 for TLG), 
which suggests that TLG was better index for predicting PFS.
DISCUSSION
In this study, we found that the metabolic tumor burden 
expressed as TLG can predict PFS and developing gefitinib 
resistance in EGFR-mutant NSCLC patients treated with first-
line gefitinib. TLG was also an independent prognostic factor 
for PFS. To the best of our knowledge, this is the first report 
demonstrating that TLG can serve as a predictor of gefitinib 
resistance in EGFR-mutant NSCLC.
Several studies have addressed the clinical signifi-
cance of TLG as determined by FDG-PET in NSCLC.13,22–26 
TLG may be prognostic for OS in nonsurgical patients with 
NSCLC.22,23 In this study, TLG was significantly associated 
with OS, suggesting that TLG shows both predictive and prog-
nostic values in EGFR-mutant NSCLC. The response rate to 
cytotoxic chemotherapy was not statistically associated with 
TLG.23 The results of current study are consistent with prior 
studies.13,22–26 Thus, taken together with our present results, 
TLG might be one of the most useful FDG-PET parameters 
for prognostication in advanced NSCLC.
Several studies27,28 have shown that SUVmax was also 
useful for predicting the clinical outcome of gefitinib in the 
patients with NSCLC. Low SUVmax was associated with 
higher response rate and prolonged PFS for gefitinib.27 Early 
change of SUVmax after 2days of gefitinib was also useful 
to predict clinical outcome.28 In this study, SUVmax was 
associated with prolonged PFS of gefitinib but not with OS. 
However, TLG that reflects both the metabolic activity and 
tumor burden showed significant association with OS and 
PFS. This suggested that TLC can be better index for predict-
ing survival outcome of first-line gefitinib than SUVmax.
Even though the response rate to EGFR TKIs in EGFR-
mutant NSCLC is approximately 60% to 80%,4–6 which is 
much higher than conventional cytotoxic chemotherapy, the 
median PFS with EGFR TKIs has been consistently known 
to be 9 to 11 months,4–6 and all patients who initially respond 
to EGFR TKIs eventually develop resistance. The range of 
PFS is wide, and clinicians have difficulty in predicting when 
resistance will occur during EGFR TKI therapy in individual 
patients. Hence, monitoring and predicting when EGFR TKI 
resistance will develop are clinically important issues. In our 
previous report,8 tumor burden, expressed as the number of 
metastatic sites, is a predictor of poor survival in NSCLC 
patients with sensitive EGFR mutations who are treated with 
gefitinib. In this regard, TLG, which reflects both metabolic 
activity and tumor burden, can be a predictor for timing of 
EGFR TKI resistance.
In general, tumor cells under selective pressure from 
EGFR TKIs have undergone a genotypical evolution. In the 
evolutionary model of resistance during EGFR TKI therapy, 
the T790M mutation has been identified in approximately 1 of 
3 million cells,29 which suggests that resistant mutant clones 
increase in proportion to the tumor burden. In an animal 
model, a large tumor burden would be more likely to have 
TABLE 1.  Clinicopathologic Characteristics of Enrolled 
Patients
N = 75 No. of Patients (%)
Age (years) Median age (range) 68 (39–88)
Sex Male 25 (33.3)
Female 50 (66.7)
Status Recurred 9 (12.0)
Initial stage IIIB, IV 66 (88.0)
Smoking Never or light smoker 60 (80.0)
Current or ex-smoker 15 (20.0)
Pathology Adenocarcinoma 64 (85.3)
NSCC NOS 9 (12.0)
Squamous cell carcinoma 1 (1.3)
Pleomorphic carcinoma 1 (1.3)
ECOG PS 0 15 (20.0)
1 44 (58.7)
2 13 (17.3)
3 3 (4.0)
EGFR mutation Deletion 19 44 (58.7)
Exon 21, L858R 31 (41.3)
SUVmax Median (range) 10.6 (1.1–25.4)
Tertile cutoff 9.0/13.4
TLG Median (Range) 204.8 (3.1–8663.0)
Tertile cutoff 102.8/455.1
NSCC NOS, non–small-cell carcinoma not otherwise specified; ECOG PS, Eastern 
Cooperative Oncology Group Performance Status; EGFR, epidermal growth factor 
receptor; TLG, total lesion glycolysis; SUVmax, maximal standardized uptake value.
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genetically complex tumors that would exhibit either primary 
or secondary resistance to erlotinib.30 Because the possibility 
of tumor heterogeneity is higher in patients with a large tumor 
burden, the likelihood of developing EGFR TKI resistance 
may be higher. Hence, patients with a high TLG and higher 
tumor burden can be genetically more unstable in terms of 
intratumoral/intertumoral heterogeneity, and it is speculated 
that these patients show shorter PFS with EGFR TKIs, but 
nevertheless higher response rates. Tumors may exhibit differ-
ent mechanisms of resistance at different sites within a patient 
because of genetic heterogeneity.7
This study has several limitations, including a retro-
spective design in a single institution and small number of 
patients that might weaken the statistical significance of TLG. 
In addition, the optimal cutoff of TLG for PET/CT needs to 
be standardized. However, in our study, the patient population 
might be more homogeneous; all patients had EGFR muta-
tions and received gefitinib as a first-line treatment. To our 
knowledge, this is the first study to have clarified the clinical 
significance of TLG in EGFR-mutant NSCLC patients treated 
with first-line EGFR TKIs.
In conclusion, our study indicates that metabolic 
tumor burden expressed as TLG is predictive of PFS, and a 
high TLG is significantly associated with reduced survival in 
EGFR-mutant NSCLC patients treated with first-line gefitinib. 
NSCLC patients with high TLG may experience early develop-
ment of EGFR TKI resistance. Baseline metabolic tumor bur-
dens measured with TLG before EGFR TKI therapy will be of 
value in predicting the development of EGFR TKI resistance. 
These results need to be validated in a prospective study.
TABLE 2.  Treatment Outcomes According to SUV and TLG Groups
N = 75
Low TLG  
1st Tertile
Int. TLG  
2nd Tertile
High TLG  
3rd Tertile Pa
Low SUVmax  
1st Tertile
Int. SUVmax  
2nd Tertile
High SUVmax  
3rd Tertile Pa
Age (yrs) Median (range) 67 (39–88) 72 (41–86) 67(43–81) 0.709 67 (41–86) 68 (39–88) 72 (43–82) 0.817
Sex Male 6 (24.0) 9 (36.0) 10 (40.0) 0.458 9 (36.0) 5 (20.0) 11 (44.0) 0.186
Female 19 (76.0) 16 (64.0) 15 (60.0) 16 (64.0) 20 (80.0) 14 (56.0)
Status Recurred 6 (24.0) 1 (4.0) 2 (8.0) 0.071 7 (28.0) 0 (0.0) 2 (8.0) 0.007
Initial stage IIIB, IV 19 (76.0) 24 (96.0) 23 (92.0) 18 (72.0) 25 (100.0) 23 (92.0)
Smoking Never or light smoker 20 (80.0) 21 (84.0) 19 (76.0) 0.779 20 (80.0) 22 (88.0) 18 (72.0) 0.368
Current or ex-smoker 5 (20.0) 4 (16.0) 6 (24.0) 5 (20.0) 3 (12.0) 7 (28.0)
Pathology Adenocarcinoma 22 (88.0) 23 (92.0) 19 (76.0) 0.487 23 (92.0) 23 (92.0) 16 (64.0) 0.153
NSCC NOS 3 (12.0) 1 (4.0) 5 (20.0) 1 (4.0) 2 (8.0) 6 (24.0)
Squamous cell carcinoma 0 (0.0) 0 (0.0) 1 (4.0) 0 (0.0) 0 (0.0) 1 (4.0)
Pleomorphic carcinoma 0 (0.0) 1 (4.0) 0 (0.0) 1 (4.0) 0 (0.0) 0 (0.0)
ECOG PS 0–1 22 (88.0) 18 (72.0) 19 (76.0) 0.356 19 (76.0) 20 (80.0) 20 (80.0) 0.924
2–4 3 (12.0) 7 (28.0) 6 (24.0) 6 (24.0) 5 (20.0) 5 (20.0)
Treatment 
response
Responder (CR + PR) 17 (68.0) 19 (76.0) 17 (68.0) 0.274 18 (72.0) 16 (64.0) 18 (72.0) 0.793
Nonresponder (SD + PD) 6 (24.0) 4 (16.0) 8 (32.0) 5 (20.0) 7 (28.0) 6 (24.0)
Not evaluable 2 (8.0) 3 (12.0) 0 (0.0) 2 (8.0) 2 (8.0) 1 (4.0)
PFS Median PFS (95% CI) 24.2 (9.9–38.4) 11.9 (10.2–13.6) 7.2 (4.0–10.5) <0.001 24.2 (13.2–35.2) 11.4 (8.6–14.1) 8.5 (6.4–10.6) <0.001
OS Median OS (95% CI) NR 31.8 (20.7–42.9) 18.8 (9.7–27.9) 0.005 40.3 (20.2–60.4) 30.0 (16.7–43.3) 24.5 (20.9–28.1) 0.194
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; OS, overall survival; CI, confidence interval; NR, not 
reached; TLG, total lesion glycolysis; SUVmax, maximal standardized uptake value; ECOG PS, Eastern Cooperative Oncology Group performance status; NSCC NOS, non–small-cell 
carcinoma not otherwise specified.
aP-value based on analysis of variance, otherwise based on χ2 test.
FIGURE 1.  Progression-free survival (A) and overall 
survival (B) of gefitinib by total lesion glycolysis (TLG).
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